Venopulmonary Artery Extracorporeal Life Support (VPa ECMO): A Novel Strategy for Refractory Hypoxemia Complicating VV ECMO

Leonardo Alberto Salazar Rojas,Dafna Isvevia García Gómez,Yuri Valentina Pinzon Martinez,Julie Pauline Lasso Perdomo,Juan Carlos Soto Ramirez,Tamar Gorgadze,Mary Alejandra Mendoza Monsalve,Raul Fernando Vasquez Rincon,Mario Alberto Castillo Blanco,Camilo Ernesto Pizarro Gomez,Anderson Bermon Angarita
DOI: https://doi.org/10.1097/mat.0000000000002125
2024-01-23
ASAIO Journal
Abstract:Refractory hypoxemia (RH) during venovenous extracorporeal membrane oxygenation (VV ECMO) support is a complex problem that limits the benefit of this therapy. The need for sustained deep sedation and delays in active rehabilitation are considered as a direct consequence of RH. Changing from VV ECMO to a configuration that returns the flow to pulmonary artery, such as venopulmonary extracorporeal membrane oxygenation (VPa ECMO) may decrease recirculation and improve systemic oxygen delivery. We present a retrospective report that describes the impact of VPa ECMO on oxygenation during sedation withdrawal in 41 patients who received VV ECMO for coronavirus disease 2019 (COVID-19). We evidenced that arterial oxygen pressure (PaO 2 ) increased from 68 to 112.3 mm Hg ( p = 0.001) with a reduction of ECMO flow (5.7–4.8 L/m; p = 0.001). Other findings included lower rates of depth sedation (Richmond Agitation Sedation Scale [RASS] ≤3, 37–63%; p = 0.007) and lower requirement inotropic support assessed by LVIS score (4.7–1.1; p = 0.005). Discharge survival was 54% with a sustained benefit until day 79. This cannulation strategy improved effectively PaO 2 in this cohort, it may be an alternative in patients with RH in VV ECMO.
engineering, biomedical,transplantation
What problem does this paper attempt to address?